title: [Treatment of pancreatic cancer. Actuality and perspective].
abstract: Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest solid malignancies, with an extremely poor prognosis, with a 1-year survival rate of approximately 20%. Low survival rates of PDAC mainly derive from late diagnosis, with only a minority of patients amenable to surgery, as well as high rates of relapse and lack of effective treatments for advanced disease stages. As a result, there is an urgent need for the development of new effective therapies. At present, the greatest step towards an improvement of treatment has been made with the introduction of two combination chemotherapy regimens, namely FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) and gemcitabine/nab-paclitaxel. However, current research is also taking a multidirectional approach aiming at developing new treatment options, such as the use of agents targeting the oncogenic network signaling of KRAS or the extracellular matrix, as well as immune therapies.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bittoni
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Andrikou
authors.forename: Andrea
authors.initials: A
authors.lastname: Lanese
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.forename: Chiara
authors.initials: C
authors.lastname: Pellei
authors.forename: Luca
authors.initials: L
authors.lastname: Faloppi
authors.forename: Michela
authors.initials: M
authors.lastname: Del Prete
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D006801:Humans; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011379:Prognosis